Compare TEVA & RBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | RBA |
|---|---|---|
| Founded | 1901 | 1958 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 20.0B |
| IPO Year | N/A | 1998 |
| Metric | TEVA | RBA |
|---|---|---|
| Price | $28.38 | $99.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $27.00 | ★ $122.00 |
| AVG Volume (30 Days) | ★ 11.4M | 967.4K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.24% |
| EPS Growth | N/A | ★ 14.05 |
| EPS | 0.62 | ★ 2.10 |
| Revenue | ★ $16,776,000,000.00 | $4,528,900,000.00 |
| Revenue This Year | $4.74 | $6.20 |
| Revenue Next Year | $0.48 | $4.20 |
| P/E Ratio | ★ $46.12 | $47.46 |
| Revenue Growth | 0.02 | ★ 8.26 |
| 52 Week Low | $12.47 | $86.68 |
| 52 Week High | $28.68 | $119.58 |
| Indicator | TEVA | RBA |
|---|---|---|
| Relative Strength Index (RSI) | 80.93 | 51.66 |
| Support Level | $24.01 | $97.32 |
| Resistance Level | $26.96 | $99.09 |
| Average True Range (ATR) | 0.68 | 1.68 |
| MACD | 0.19 | 0.42 |
| Stochastic Oscillator | 94.65 | 75.43 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
RB Global has evolved into a leading global marketplace that connects buyers and sellers of commercial assets and vehicles. It is the result of the 2023 combination of Ritchie Bros. and IAA. Ritchie Bros.' roots were as an auctioneer facilitating transactions of commercial, construction, and transportation equipment (excavators, bulldozers, forklifts, and commercial trucks and trailers). However, it has evolved into an omnichannel marketplace. IAA has similar roots, though primarily focused on the salvage auction segment for consumer automobiles. The group provides ancillary services including title processing, transportation/towing, financing, data and appraisal, and so on. Its activities are international, though skewing approximately two-thirds to North America.